Skip to content

Study · Randomized controlled trial · 2018

4 results

Efficacy and safety of adding liraglutide to existing insulin regimens in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of a phase 3 randomized clinical trial.

Kaneko S, Nishijima K, Bosch-Traberg H, Kaku K, Seino Y

Journal of diabetes investigation5 Feb 2018Cited by 6 (Europe PMC)

PMID29277968 (opens in a new tab)PMCIDPMC6031509 (opens in a new tab)DOI10.1111/jdi.12793 (opens in a new tab)PepBankPUB-29277968
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes on insulin, adding liraglutide reduced glycated hemoglobin versus placebo in all three insulin regimens, with placebo-corrected reductions from -1.45 to -1.17% at 16 weeks, maintained at 36 weeks.

    In plain wordsIn Japanese adults with type 2 diabetes on insulin, adding liraglutide lowered glycated hemoglobin more than placebo in all insulin regimens.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction, placebo-corrected, at 16 weeks
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.9 mg/day · 36 weeksAs given in this study (human).

    Source sentences

    Summary
    Comparing liraglutide with a placebo, liraglutide was associated with glycated hemoglobin reduction in all insulin regimens, with placebo-corrected reductions at 16 weeks ranging from -1.45 to -1.17%, and maintained at 36 weeks.
    2 context sentences
    Summary · context
    In this post-hoc analysis, results from a 36-week, randomized, double-blind, placebo-controlled, parallel-group trial are reported.
    Summary · context
    Individuals with type 2 diabetes mellitus were stratified according to their pre-trial insulin regimen (basal, basal-bolus and premix).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes on insulin, liraglutide gave a greater reduction in mean plasma glucose from seven-point self-monitoring than placebo.

    In plain wordsIn Japanese adults with type 2 diabetes on insulin, liraglutide lowered average blood glucose more than placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseMean plasma glucose (seven-point self-monitoring)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.9 mg/day · 36 weeksAs given in this study (human).

    Source sentences

    Summary
    Liraglutide resulted in a greater reduction in mean plasma glucose obtained from seven-point self-monitoring
    2 context sentences
    Summary · context
    In this post-hoc analysis, results from a 36-week, randomized, double-blind, placebo-controlled, parallel-group trial are reported.
    Summary · context
    Individuals with type 2 diabetes mellitus were stratified according to their pre-trial insulin regimen (basal, basal-bolus and premix).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes on insulin, a greater proportion of patients on liraglutide reached target glycated hemoglobin than on placebo.

    In plain wordsIn Japanese adults with type 2 diabetes on insulin, more people reached their glycated hemoglobin target with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseProportion reaching target HbA1c
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    0.9 mg/day · 36 weeksAs given in this study (human).

    Source sentences

    Summary
    greater proportions of patients achieved target glycated hemoglobin.
    2 context sentences
    Summary · context
    In this post-hoc analysis, results from a 36-week, randomized, double-blind, placebo-controlled, parallel-group trial are reported.
    Summary · context
    Individuals with type 2 diabetes mellitus were stratified according to their pre-trial insulin regimen (basal, basal-bolus and premix).
  4. 04HumanRandomized controlled trialSafety outcome

    In Japanese adults with type 2 diabetes on basal or basal-bolus insulin, slightly higher proportions reported confirmed hypoglycemia with liraglutide than with placebo from 0 to 16 weeks.

    In plain wordsIn Japanese adults with type 2 diabetes on basal or basal-bolus insulin, slightly more people had confirmed low blood sugar with liraglutide than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseConfirmed hypoglycemia, week 0 to 16
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    0.9 mg/day · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    With liraglutide, slightly higher proportions of patients receiving basal and basal-bolus insulin reported confirmed hypoglycemia from 0 to 16 weeks.
    2 context sentences
    Summary · context
    In this post-hoc analysis, results from a 36-week, randomized, double-blind, placebo-controlled, parallel-group trial are reported.
    Summary · context
    Individuals with type 2 diabetes mellitus were stratified according to their pre-trial insulin regimen (basal, basal-bolus and premix).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01572740

Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 2575 Apr 2012 to 27 Mar 2013

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 7 Feb 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.